-
Vir Biotechnology director Saira Ramasastry resigns; board shrinks to 7; annual meeting elects directors
Saira Ramasastry steps down from board and audit committee effective May 26, 2026, due to business conflict; no disagreement with company.
-
Vir Bio Q1 net loss $125.7M; cash $809.3M; positive CHD data; VIR-5500 collaboration closed
Net loss of $125.7M ($0.85 per share) vs $121M ($0.88) in Q1 2025.
-
Vir Biotechnology CMO Mark Eisner to step down effective April 24, 2026
Mark Eisner, EVP and Chief Medical Officer, leaving role on April 24, 2026.
-
Vir Bio appoints CEO Marianne De Backer to additional role of President
On March 4, 2026, Vir Bio's Board appointed CEO Marianne De Backer to the additional position of President.
-
Vir Biotechnology closes $172.5M equity offering; underwriters exercise full over-allotment
Sold 20,294,117 shares of common stock at $8.50 per share, raising ~$172.5M in gross proceeds.
-
Vir Biotechnology prices $150M public offering of 17.6M shares at $8.50/share
Offering of 17,647,059 shares of common stock at $8.50 per share; over-allotment option for 2,647,058 shares.
-
Vir Biotechnology enters global strategic collaboration with Astellas for VIR-5500 prostate cancer T-cell engager
Vir Bio will receive $335 million in upfront and near-term payments, including $240M cash and $75M equity at 50% premium.
-
Vir Bio: 88% HDV RNA undetectable at Week 96 in combo arm; cash ~$781M, runway to Q4 2027
Phase 2 SOLSTICE: 88% (21/24) of combo arm achieved undetectable HDV RNA at Week 96 vs 46% (11/24) monotherapy.
-
Vir Bio licenses CHD combo to Norgine for EUR 55M upfront, up to EUR 495M milestones; cash runway extended to Q4 2027
Exclusive commercial license for tobevibart+elebsiran in Europe, Australia, New Zealand for chronic hepatitis delta.
-
Vir Biotech Q3 net loss $163M ($1.17/sh); ECLIPSE enrollment ahead of schedule
Net loss $163.1M ($1.17/sh) vs $213.7M ($1.56) in Q3 2024; revenues $0.2M.
-
Vir Biotechnology Q2 net loss $111.0M; cash $892.1M; ECLIPSE program underway
Net loss $111.0M ($0.80/share) vs $138.4M ($1.02) in Q2 2024; revenue $1.2M down from $3.1M.
-
Vir doses first patient in Phase 1 trial of EGFR-TCE VIR-5525; triggers $75M milestone payment to Sanofi
First patient dosed in Phase 1 trial of VIR-5525, a dual-masked T-cell engager targeting EGFR, in solid tumors (NSCLC, CRC, HNSCC, cSCC).
-
Vir Biotechnology stockholders elect directors, approve executive pay, ratify auditor at 2025 annual meeting
Jeffrey S. Hatfield and Saira Ramasastry elected as Class III directors each with >93 million votes for.
-
Vir Biotech reports HBsAg loss in MARCH study but halts Phase 3 for chronic HBV without partner
HBsAg loss 24 weeks post-treatment: 17% (3/18) and 21% (3/14) in low baseline HBsAg patients with tobevibart+elebsiran without/with PEG-IFNα.
-
Vir Biotech Q1 net loss $121M; launches Phase 3 hepatitis delta program; cash into mid-2027
Net loss of $121.0M ($0.88 per share) vs $65.3M ($0.48) in Q1 2024; revenue $3.0M vs $56.4M.
-
Vir Biotechnology reports Q4 and full year 2024 financial results and pipeline updates
Cash, cash equivalents and investments of $1.10 billion as of Dec 31, 2024, providing cash runway into mid-2027.
-
Vir Biotechnology CTO to depart Feb 26; Maninder Hora appointed as replacement
Ann (Aine) M. Hanly, EVP and Chief Technology Officer, will leave Vir Biotechnology on February 26, 2025.
-
Vir Biotech reports encouraging Phase 1 data: 50% tumor shrinkage (VIR-5818), 58% PSA50 (VIR-5500)
VIR-5818 (HER2): 50% (10/20) tumor shrinkage at doses ≥400 µg/kg; cPR in 33% (2/6) HER2+ CRC.
-
Vir Biotech Q3 net loss $213.7M; closes Sanofi TCE licensing deal, appoints new CFO
Net loss $213.7M ($1.56 per share) vs $163.4M ($1.22) in Q3 2023; revenue $2.4M, down from $2.6M.
-
Vir closes $100M Sanofi license deal for three T-cell engagers; appoints new CFO
Closed exclusive worldwide license with Sanofi for 3 clinical-stage masked TCEs (SAR446309, SAR446329, SAR446368) and PRO-XTEN platform for oncology/infectious disease.
-
Vir Biotechnology licenses three clinical-stage masked T-cell engagers from Sanofi for $100M upfront
Upfront payment of $100M plus $75M escrowed milestone for SAR446368 (AMX-525) first-in-human dosing by 2026.
-
Vir Bio Q2 net loss narrows to $138M; initiates restructuring cutting 25% of workforce
Net loss of $138.4M ($1.02/sh) vs $194.8M ($1.45/sh) in Q2 2023; cash and investments $1.43B, down $78M in quarter.
-
Vir Biotech gets FDA IND clearance & Fast Track for hepatitis delta combo therapy
FDA cleared IND and granted Fast Track for tobevibart + elebsiran for chronic hepatitis delta.
-
Vir reports high virologic response in Phase 2 SOLSTICE hepatitis delta trial
De novo tobevibart+elebsiran combination: 64% (7/11) combined endpoint at week 24.
-
Vir Biotechnology shareholders elect Class II directors, approve advisory compensation, ratify EY
Directors De Backer, Bischofberger, Farid, Nelsen elected with votes for/withheld: 105.6M/1.1M, 80.0M/26.7M, 106.4M/0.3M, 67.9M/38.8M; broker non-votes 12.3M.